Data show achievement of primary endpoint, demonstration of functional microbiota restoration, inflammation reduction and positive safety profile in acute myeloid…
Categorie
2018
Lyon, France, November 2, 2018 – MaaT Pharma announced today that the company will present a poster summarizing the complete…
November 6, 2018
Microbiome restoration biological drug product to be tested for safety and overall survival impact in patients with acute Graft-versus-Host-Disease. Lyon,…
October 12, 2018
Results from in silico analysis using MaaT Pharma’s data analysis platform, GutPrint, demonstrate therapeutic rationale and manufacturing capabilities of developing…
September 18, 2018
MaaT Pharma receives world-wide exclusive license to technology co-developed with hematology and gastroenterology departments of Saint-Antoine Hospital, Paris.
June 21, 2018
Dr. Joël Doré, MaaT Pharma’s co-founder, received awards for his work Created in the end of December 2014, MaaT…
May 18, 2018
MaaT Pharma, a clinical-stage biopharmaceutical company, received authorization from competent authorities to launch its phase II prospective multicenter clinical trial…
March 5, 2018
We are a clinical-stage microbiome therapeutics company aiming to improve survival in cancer.
Ressources
Contact
Nous sommes une société au stade clinique, spécialisée dans les thérapies issues du microbiote dédiées aux patients atteints de cancer.
Contact
Nous sommes une société au stade clinique, spécialisée dans les thérapies issues du microbiote dédiées aux patients atteints de cancer.